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E-mail: ePurpose: To develop and evaluate a method for adding dose distributions of combined external beam radiotherapy
(EBRT) and brachytherapy (BT) for oropharyngeal patients.
Methods and Materials: Two computed tomography (CT) scans were used for 5 patients: the EBRT CT, used for
EBRT planning, and the BT CT, acquired after catheter implantation. For each scan, the salivary glands and the
chewing and swallowing muscles were contoured, and a dose distribution was calculated. A nonrigid transforma-
tion was obtained by registering the organs’ surfaces. Then the BT dose distribution was mapped onto the EBRT
dose distribution by applying the transformation obtained. To account for differences in fractionation, the physical
doses were converted to equivalent dose in 2Gy (EQD2), and the total dose was found by adding dose voxel by voxel.
The robustness of the dose addition was investigated by varying delineations and input parameters of the
registration method and by varying the a/b parameter for EQD2. The effect of the perturbations was quantified
using dose–volume histograms (DVH) and gamma analyses (distance-to-agreement/dose-difference = 1 mm/1 Gy).
Results: The variations in input parameters and delineations caused only small perturbations in the DVH of the
added dose distributions. For most organs the gamma index was low, and it was moderately elevated for organs
lying in areas with a steep gradient (median gamma index#2.3 for constrictor muscles,#0.7 for all other organs).
Conclusions: The presented method allows adding dose distributions of combined EBRT and BT for oropharyn-
geal patients. In general, the method is reliable and robust with respect to uncertainties in organ delineation,
perturbations in input parameters of the method, and a/b values.
 2011 Elsevier Inc. Open access under the Elsevier OA license.Three-dimensional dose addition, Nonrigid registration, Head and neck, Brachytherapy.INTRODUCTION
A combination of external beam radiotherapy (EBRT) and
brachytherapy (BT) is commonly used in the treatment of
head-and-neck cancer, cervical cancer, and prostate cancer
(1–3). EBRT aims at treating the primary tumor and areas
at risk for microscopic disease, whereas BT is used to
boost the primary tumor. However, in current clinical
practice, BT boosts are optimized independently, and the
dose already delivered is not accounted for. The reason is
that the addition of three-dimensional (3D) dose distribu-
tions is challenging because of anatomic changes in the
patient caused, for instance, by weight loss, tumor shrinkage,
different patient setups, implantation of catheters, insertion
of applicators, or surgical procedures (Fig. 1). Furthermore,
to establish dose–effect relationships for tumor control and
side effects in combined modality treatments, simplet requests to: Eliana M. Vasquez Osorio, B.Sc., Erasmus
enter - Daniel den Hoed Cancer Center, Department of
Oncology, Groene Hilledijk 301, 3075 EA Rotterdam,
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1268approximations to add dose are often used (4, 5). Some
studies use only the EBRT dose to establish dose–effect
relationships (4). In other studies, the accumulated dose
was approximated without taking patient deformations into
account. For example, Teguh et al. (5) related the probability
of dysphagia to the dose to the swallowing muscles, where
the total dose was found by simply adding the physical
EBRT and BT mean doses.
Rigid registration, including rotation and translation,
followed by the linear addition of the dose matrices, is not
accurate to add dose. A rigid transformation does not align
deforming anatomy adequately (Fig. 1). Nonrigid registra-
tion, on the other hand, allows better alignment of the anat-
omy, enabling different dose distributions to be mapped to
a common frame of reference. Additionally, different modal-
ities often use different fractionation schemes. Therefore,Conflict of interest: none.
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Fig. 1. Anatomic changes between external beam radiotherapy (EBRT) and brachytherapy (BT) for 2 patients. First row,
sagittal planes of Patient 1. Notice the large anatomic changes between the EBRT and BT computed tomography (CT)
scan, mostly caused by neck dissection, catheter insertion, and different patient positioning. Second row, axial planes
of Patient 3. Notice that rigid registration (last column) is not adequate to align both CT scans.
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lent doses before adding the dose in each voxel (6).
In this article we propose a method for adding 3D EBRT
and BT dose distributions, using a nonrigid registration
framework developed in house, based on Chui et al. (7) and
previously described inVasquezOsorio et al. (8), andBondar
et al. (9). To account for the biologic effects of the different
fractionation schemes, the physical dose distributions were
converted to the biologic equivalent dose for 2-Gy fractions
(EQD2, (6)) before adding each dose voxel. The method
was tested for the organs at risk of 5 oropharyngeal cancer pa-
tients treated with EBRT, followed by BT boost (1, 5). The
robustness of the dose addition was investigated by
variations in input parameters of the registration method,
simulating variations in organ delineations around the
clinical contours, and by varying the a/b value used for
EQD2.METHODS AND MATERIALS
Patient data
Five oropharyngeal cancer patients were included in this study
(Table 1). These patients belonged to a larger group previously
used for quantifying anatomic changes using nonrigid registration
(10). According to the protocol (1, 5), the patients first underwent
EBRT to a total dose of 46 Gy in 23 fractions (dynamic intensity-
modulated RT), followed by a BT boost 2 weeks after the end of
EBRT (Pulsed dose-rate BT scheme 2 Gy + 18  1 Gy + 2 Gy, bi-
ologically equivalent to high dose-rate BT scheme 4 Gy + 4 3 Gy
+ 4 Gy (11)). node-positive patients underwent neck dissection
before catheter implantation.
Two intravenous contrast-enhanced computed tomography (CT)
scans were used for each patient: the CT scan used for planning
EBRT (EBRT CT scan), and a repeat CT scan taken 2 weeks after
EBRT, after catheter implantation, and just before BT dose delivery
(BT CT scan). The slice spacings were 3 mm and 1.5 mm for the
EBRT and BT scans, respectively. The catheters were clearly
Fig. 2. Schematic showing the steps for dose addition. BT = bra-
chytherapy; EBRT = external beam radiotherapy; EQD2 = equiva-
lent dose in 2 Gy.
Table 1. Patient characteristics
Patient Sex Age (y) Site TNM staging
1*y M 57 Base of tongue T3 N2a M0
2z M 48 Tonsillar fossa T2 N0 M0
3z F 59 Soft palate T2 N0 M0
4*yx M 58 Base of tongue T3 N2a M0
5*y F 52 Base of tongue T1 N2c M0
* Both necks treated by external beam radiotherapy.
y Patient underwent neck dissection, where, among other soft
tissues, the submandibular glands were removed.
z Ipsilateral neck treated by external beam radiotherapy.
x Patient underwent concomitant chemotherapy.
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acquisition. The body contour, chewing muscles (masseter, ptery-
goid, and temporalis muscles), swallowing muscles (superior,
middle and inferior constrictor, cricopharyngeus, and esophagus in-
let muscles), and major salivary glands (parotid and submandibular
glands) were contoured in both CT scans. For consistency, the BT
organs were delineated, using the EBRT contours as reference. All
delineations were checked by a second observer. Surfaces, defined
by sets of triangles joining contours in consecutive slices, were
created from the delineated structures.
Dose distributions for EBRT and BT were calculated using the
treatment planning system used clinically at the time: CadPlan
v6.4.7 (Varian Medical Systems, USA) and Plato BPS v14.2 (Nu-
cletron, The Netherlands), respectively. The BT dose distribution
was originally calculated based on implant reconstruction from
orthogonal radiographs. Here, we reconstructed the BT dose distri-
bution on the BT CT scan. Using the catheters in the BT CT scan,
the implant geometry and active dwell positions were determined.
The dwell times were copied from the original plan. Finally, the BT
dose was calculated and the dose grid was exported. Both dose
distributions were interpolated to a regular grid (1  1  1 mm3).Dose addition
Fig. 2 illustrates the steps to add the EBRTand BT dose distribu-
tions. First, the triangulated surfaces generated from the delineated
structures were used to compute a nonrigid transformation using
a nonrigid registration method developed in house (8, 9). The
nonrigid registration framework was previously validated using
anatomic landmarks (8) and was improved to reinforce inverse con-
sistency (9). The nonrigid transformation, modeled by a regularized
thin-plate spline (7), implicitly comprises the changes between the
two structure sets by generating a smooth spatial mapping, which is
constrained by points lying on the organs’ surface. Second, we
computed the transformed BT dose by inverse mapping using the
Insight Toolkit (12). Inverse mapping finds the transformed BT
dose in the grid positions of the EBRT dose by transforming each
grid position into the BT dose grid using the spatial mapping
defined by the EBRT to BT transformation. Then the dose is
interpolated at the mapped location using the dose of the closest
neighboring BT grid points. Finally, the interpolated value is stored
in the EBRT grid position. This procedure avoids the creation of
empty areas in the transformed dose. Third, the physical doses
were converted into EQD2 using the linear quadratic model.
Finally, the 3D total dose distribution was calculated by adding
the converted EBRT dose and the transformed and converted BT
dose voxel by voxel.Simple alternatives to full 3D nonrigid registration
We investigated the validity of approximating the D1, mean dose
and D99 by adding the separate values for the EBRT and BT dose
distributions without taking anatomic changes into account. We
defined D1 and D99 as the dose received by the 1% and 99% of
the organ’s voxels, respectively as read from the DVH data. The ap-
proximations were converted to EQD2 and then compared to the
values obtained by nonrigid registration.Robustness of dose addition
As in previous studies (8), each registration produced a nonrigid
transformation, which aligned the surfaces nicely. This was
checked by visual inspection and by assuring that the transforma-
tion error, defined as the mean distance between surfaces, was be-
low 1 mm. Previously, we validated the anatomic correspondence
of the nonrigid registration framework using identifiable landmarks
in CT datasets (8). The image sets currently used do not contain
sufficient information to indistinguishably identify corresponding
tissue elements on a functional subunit level. Alternatively, we
investigated the robustness of the dose addition method with re-
spect to changes in (1) the parameters of the nonrigid registration
framework, (2) control point distribution, (3) organ delineation,
and (4) a/b value used for EQD2. To assess the influence of these
perturbations, we compared each total dose distribution resulting
Fig. 4. Procedure to simulate delineation variations. (A) A set of
points is randomly selected (black dots) from the points in the
original structure (light triangles). Then deforming vectors,
restricted to the axial planes, are generated (thick lines), limiting
their lengths to the delineation variation simulated (1, 3, or 5
mm). (B) The deformation is interpolated to the rest of the structure
using a nonregularized thin-plate spline. (C) Brachytherapy com-
puted tomography scan of Patient 5 showing all nine delineation
variations simulated. The clinical delineation is shown in white.
Fig. 3. Gamma index 1mm\1 Gy as a function of distance and dose
difference between twovoxels. Perfect agreement scores zero (same
dose and same spatial position). Two voxels with the same dose in
locations separated by a distance of DTA, or with the same spatial
position and dose difference of DD, score a gamma index equal to
one.
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dose-volume histograms (DVH) and the gamma index method
(13). The reference total dose distribution was calculated using
the clinical delineations and reference parameters (r = 5 mm, l =
5, and a/b = 3 Gy). The gamma index combines the dose-
difference (DD) and distance-to-agreement (DTA) to compare
two dose distributions (Fig. 3). Gamma index (DTA\DD = 1
mm\1 Gy) was evaluated in each voxel within the delineated struc-
tures. We performed a total of 23 perturbations (see below for de-
tails) for each of the 5 patients, including 15 organs per patient,
which resulted in 1,725 gamma index distributions. We summa-
rized the distributions of gamma indices in box-and-whisker dia-
grams and reported the percentage of voxels passing the criteria
(gamma index #1).
Perturbations of framework parameters. The nonrigid registra-
tion framework uses points to represent the structures to be
registered. The framework includes a procedure to generate points
from surfaces that is controlled by the density radius r. The param-
eter r determines the density of control points, which affects the
computational time and accuracy. Small r means large number of
points, longer computational time, and, theoretically, more accurate
results. Conversely, large r produces few points, shorter computa-
tional time, and less accurate results. Based on previous experience,
we tested r = 5, 6, and 8 mm. The second framework parameter is l.
This weight parameter controls the degree of deformation of the
transformation function by regulating the thin-plate spline used
as transformation. Large l restricts the transformation to be mostly
affine, opposite to a small l, which relaxes the restriction. We tested
l = 0.5 and 5, which in combination with the used rs (above)
produced transformation errors below 1 mm as in Vasquez Osorio
et al. (8).
Perturbations in control point distribution. We investigated the
influence of using different control point distributions. As men-
tioned, the framework includes a procedure to generate control
points, which spread pseudohomogeneously on the surfaces of
the delineated structures (8, 9). In this procedure, a refined
surface of the structures is generated by dividing iteratively the
triangles that join the contours of consecutive slices. Then, the
vertices of the refined triangles are grouped in spheres whose
radius is the density radius (r), and the centroid is calculated.
Last, the points are replaced by the closest point on the surface tothe calculated centroid. By randomly varying the position of the
grouping spheres, we generated four control point distributions
using r = 6 mm.
Perturbations in structures delineations. To determine the
influence of delineation variations on the nonrigid registration,
and consequently on the dose addition, we simulated observer
variations of 1, 3, and 5 mm in the delineation of structures. To sim-
ulate the variations, random deformations were applied to the
surfaces of the EBRT and BT structures (Fig. 4). First, one third
of the contour points that constitute the structures’ surface was ran-
domly selected. Only points that were not in close proximity to
other organs were considered, to avoid overlapping of perturbed
contours of neighboring organs. Second, random deformation vec-
tors were generated. To simulate the real situation, the deformation
vectors were limited to the axial planes where the contours were
drawn, and their direction and length was random, to a maximum
of the variation simulated (1, 3, or 5 mm). Third, the deformation
was interpolated to the rest of the structure points using a nonregu-
larized thin-plate spline (14). Finally, the deformed structures were
used in the nonrigid registration framework to generate the nonrigid
transformation. We calculated a total of nine nonrigid
Table 2. EBRT and BT mean doses for each patient and organ
EBRT; BT mean doses (physical doses, Gy)
Organ Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Left parotid 23.7; 1.4 6.4; 0.8 11.4; 0.8 26.1; 2.5 19.4; 1.7
Right parotid 25.3; 1.4 29.5; 1.5 29.1; 1.6 35.3; 2.3 10.9; 1.5
Left submandibular 47.8; 3.2 2.5; 1.6 5.4; 1.9 44.8; 9.7 46.5; 9.0
Right submandibular 48.7; 4.6 45.3; 4.9 43.6; 9.6 45.8; 20.7 46.4; 6.7
Left masseter 27.1; 2.4 0.7; 0.9 5.4; 0.8 17.6; 2.0 12.8; 2.7
Right masseter 28.5; 2.5 11.4; 2.0 12.8; 2.0 23.7; 2.0 14.8; 2.0
Left pterygoid 31.1; 3.2 2.3; 1.7 12.3; 1.4 25.6; 2.6 13.4; 3.8
Right pterygoid 36.8; 3.3 16.1; 3.2 26.9; 3.7 39.9; 2.4 12.7; 3.4
Left temporalis 18.0; 2.0 0.5; 1.0 2.8; 0.8 20.4; 1.5 1.3; 1.8
Right temporalis 17.1; 1.9 2.3; 1.6 3.0; 1.6 21.5; 1.4 1.3; 1.7
Superior constrictor 47.3; 6.6 26.7; 7.0 33.5; 10.6 44.3; 8.8 45.7; 6.3
Middle constrictor 47.4; 4.3 21.4; 4.6 20.3; 4.7 44.7; 11.6 46.7; 4.3
Inferior constrictor 25.1; 2.5 12.3; 1.9 18.5; 1.7 42.4; 6.5 38.5; 3.4
Cricopharyngeus 17.5; 1.3 10.1; 0.8 17.3; 0.8 41.6; 2.5 29.2; 1.8
Esophagus inlet 20.1; 0.7 7.4; 0.4 16.1; 0.6 39.8; 1.2 30.7; 1.2
Abbreviations: EBRT = external beam radiotherapy; BT = brachytherapy.
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simulated maximum variation of 1, 3, and 5 mm. Calculation of
DVHs and gamma analyses were performed using the nonperturbed
delineations to assess only the effects of the perturbations on the re-
sults of the dose addition.
Perturbations in a/b values. EQD2 was used to account for dif-
ferences in the fractionation schemes for EBRT and BT. EQD2 is
based on the linear-quadratic model, and it uses the biologic
parameter a/b (15). The a/b value represents the ratio between
the radiosensitivity and the repair capacity of a specified tissue.
A common value for late reactions is 3 Gy, but the precise value
is uncertain. We investigated the effect of different a/b values on
the dose addition by varying a/b by 20% and 10% around the
reference 3 Gy. We used the nonrigid transformation applied to cal-
culate the reference total dose distribution to assess only the effects
of a/b variation.RESULTS
Total dose
Table 2 summarizes the mean doses per organ and patient
for EBRT and BT dose distributions. For all patients, the
largest contribution to the total dose came from the EBRT,
and most organs at risk received low BT doses. Steep gradi-
ents were present in the BT dose distribution, especially
within the constrictor muscles (up to 29, 88, and 22 Gy/
mm for Patients 2, 3, and 4 respectively). The gradients
were caused by the closeness of implanted catheters to the
muscles (Fig. 1). Fig. 5 shows the DVHs for the total dose
distributions. The largest total doses were found for the
constrictor muscles for Patients 3 and 4, and for the right
submandibular gland for Patient 3.
We summarized the differences between calculating D1,
the mean dose, and D99, taking anatomic changes into
account and ignoring anatomic changes in Table 3. None
of the DVH parameters were systematically underestimated
or overestimated by the approximation, but large differences
were found for D1.Perturbations analysis
Besides the DVHs for the reference total dose distribu-
tions, Fig. 5 also shows the total dose DVHs for the 23
perturbations. Most perturbations produced only minor devi-
ations with respect to the reference DVHs, to the point at
which most total dose DVHs blend into one single curve.
The largest variations were found for the middle and inferior
constrictor muscles for Patient 4 (framework parameters per-
turbation l = 0.5), the right submandibular glands for Patient
3 (delineation variations of 5 mm), and the pterygoid, and
temporalis muscles for the a/b perturbations.
Figs. 6 and 7 summarizes the distributions of gamma
indices of all voxels of all organs and patients (>21 million
voxels) using box-and-whisker diagrams categorizing the
data by perturbation type and by organ per patient, respec-
tively. The perturbations in the control point distributions
produced the lowest gamma indices. The largest gamma
indices were found for a/b = 2.4 Gy, perturbations using
l = 0.5 and delineation variations of 5 mm (medians and
boxes in Fig. 6). The results varied among patients. Patient
4 presented the largest variations and Patient 1 the smallest;
and both were base of tongue cases. All chewingmuscles, the
parotid glands, the esophagus inlet, and the cricopharyngeus
muscles presented small gamma indices for all patients. The
organs that presented the most variation were the constrictor
muscles and the submandibular glands. Similar results were
found when each perturbation was independently analyzed
(total, 1,725 medians; data not shown). The largest gamma
indices were found for the middle and inferior constrictor
muscle for Patient 4, framework parameters r = 5, l = 0.5
(medians up to 2.3 and 2.2). For the rest of the organs for
all perturbations and patients, the median was below 0.7.
Table 4 summarizes the voxels passing the strict criteria of
the gamma analyses. Most organs scored high values. The
lowest values were found for the constrictor muscles using
l = 0.5 and delineation variation of 5 mm, which is in
accordance with the data shown in Figs. 6 and 7.
Fig. 5. Dose–volume histograms for the total dose distributions (reference and 23 perturbations). Perturbations on the
total dose are shown in different shades of gray, and most of them blend with the reference dose–volume histogram curve.
Dose axes were cropped to the largest D1. EQD2 = equivalent dose in 2 Gy.
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We presented a method for adding dose distributions of
different modalities, taking into account anatomic changesand biologic effects. The method was applied to the organs
at risk of 5 patients with oropharyngeal cancer. A robustness
analysis was presented as an alternative to validation against
Table 3. Differences between approximated D1, mean dose
and D99 and D1, mean dose, and D99 calculated using
nonrigid registration
Differences (EQD2,* Gy)
DVH parameter Average Range
D1 0.9 14.5 to 25.6y
Mean dose 0.1 2.6 to 0.4
D99 0.1 1.7 to 1.5
Abbreviation: DVH = dose–volume histogram.
* Using a/b = 3 Gy.
y MaximumD1 occurred in middle constrictor muscle for Patient
3, shown in lower row in Fig. 1.
Fig. 6. Distributions of gamma indices 1 mm\1 Gy categorized by
perturbation type. The dots represent the median; the boxes extend
between the 25th and 75th percentiles and the whiskers between the
0.1 and 99.9 percentiles for all voxels of all organs and patients.
Whiskers extending beyond the axis are marked with ^ and their
99.9 percentile is shown next to them.
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bations of the input parameters and delineation variations, as
demonstrated by the overlapping total dose DVH curves in
Fig. 5. Robustness was also investigated by gamma analyses
(Figs. 6 and 7), comparing perturbed and reference dose
distributions using strict criteria (i.e., 1 mm\1 Gy).
Comparing the perturbation types (medians and boxes in
Fig. 6), larger gamma indices were found for a/b variations,
l = 0.5, and the largest delineation variations (5 mm). The l
parameter controls the flexibility of the transformation, and
a low l produces a more flexible transformation. Compared
to the reference dose distributions, total doses calculated
by transformations using l = 0.5 showed larger local
differences, resulting in larger gamma indices (whiskers in
Fig. 6). The gamma indices were low for the perturbations
in control point distributions, l= 5, and delineationvariations
below 5mm. Table 4 shows similar results for the percentage
of voxels passing the gamma criteria, except for the a/b
parameter. Although a/b perturbations produced the largest
medians and boxes in Figs. 5 and 6, they scored 100% of
voxels passing the gamma criteria. An explanation is that
the a/b perturbation affected the whole dose distribution,
but the change was below the criteria used for the gamma
analyses (1 mm\1 Gy). For the organs studied, the
variations caused by the a/b perturbations in the total dose
distributions were small (below 1 Gy around 1 mm) and
could be seen as clinically not relevant. However, the
variations may become greater when adding doses of larger
magnitude because of the quadratic form of EQD2.
Large variations were found in the constrictor muscles and
some submandibular glands (Figs. 5 and 7). These organs
were close to the target volume, to the extreme that some
catheters run shortly along the swallowing muscles,
causing a very steep BT dose gradients within these
muscles: up to 29, 88, and 22 Gy/mm for Patients 2, 3, and
4 respectively. The location of these organs explains the
enhanced effect of the perturbations, especially for those
where local differences were present (framework
parameters and delineation variations), because even small
changes in these areas with steep gradients result in very
large variations. A possibility for improving the dose
addition in areas with steep gradients is to use a different
interpolation method for mapping the BT dose (Fig. 2,step 2) for instance octant interpolation as proposed by
Rosu et al. (16). The concept of accumulating dose using
nonrigid registration has been explored in the literature.
However, to our knowledge, there has been no previous at-
tempt to add 3D dose distributions of EBRT and BT taking
anatomic changes into account. Few reports are available
that address the anatomic validity of dose addition. Schaly
et al. (17) proposed tracking of tissue elements (voxels) be-
tween daily CT scans and accumulation of their dose distri-
butions using thin-plate spline. In a sensitivity analysis of
control point placement, they found dose differences up to
37% for bladder and 27% for rectum. An alternative ap-
proach for dose accumulation uses finite element analysis
(18). However, inclusion of anatomic landmarks inside or
outside the surfaces is limited, and the mechanical properties
for the tissue should be accurate (19).
With respect to the current study, our nonrigid registration
method was previously validated using anatomic landmarks
(8). Recently Zhong et al. (20) suggested that using
landmark-based evaluation of nonrigid registrations may
potentially underestimate registration errors, because large
errors can bemade in areas with few anatomic features (areas
of relatively uniform intensity). In their study, they created
a displacement vector field to create phantoms that were reg-
istered. The vector field was then used as a ground truth to
compare registration results. In clinical practice (e.g., in
our study), such artificial displacement fields are not avail-
able for real patient data, and the validation still depends
on visual anatomic landmarks. It has been shown in the liter-
ature that the registration error increases as its distance from
the boundary of organs increases (19, 20). However, the
organs analyzed in the current study are small or narrow;
therefore, most points are relatively close to the boundary.
The validation for the cases of head-and-neck cancer in
Vasquez Osorio et al. (8) used points representing the top
Fig. 7. Distributions of gamma indices 1 mm\1 Gy categorized by organs and perturbation type per patient. See Fig. 6 for
information about the diagram.
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ble–parotid gland and styloid process—parotid gland inter-
faces. These lines lay on the surface, and the points were
close to the glands’ surfaces. Therefore, it can be argued
that for cases of head-and-neck cancer, no validation has
been made for points inside the organs. On the other hand,
the method was validated for larger organs using internallandmarks (cervix and prostate). Moreover, it has been
shown that the results of the method can be improved by in-
corporating additional anatomic information in the nonrigid
registration, such as internal anatomic landmarks, repre-
sented by lines or points. As an alternative to anatomic val-
idation, in the current study we investigated the robustness of
the dose addition method. To further validate the method and
Table 4. Percentage of voxels passing the strict gamma criteria (1mm\1 Gy) for all patients, categorized by perturbation type
Average(standard deviation) of percentage of voxels that gamma index (1 mm\1 Gy) #1 (in %)
Framework parameters Control Delineation variation
Organ l = 5* l = 0.5* pointsy 1 mmz 3 mmz 5 mmz a/b valuex
Submandibular glands
Left 99.4 (1.7) 97.7 (4.2) 99.6 (1.1) 99.5 (1.9) 99.2 (2.3) 96.2 (7.3) 100.0 (0.0)
Right 99.2 (1.7) 94.2 (3.5) 99.8 (0.4) 99.0 (1.7) 92.2 (9.3) 85.3 (12.1) 100.0 (0.0)
Pterygoid muscle
Left 100.0 (0.0) 99.9 (0.2) 100.0 (0.0) 100.0 (0.0) 100.0 (0.1) 99.5 (0.9) 100.0 (0.0)
Right 100.0 (0.1) 98.8 (2.3) 100.0 (0.0) 100.0 (0.0) 99.7 (0.7) 99.2 (2.4) 100.0 (0.0)
Constrictor muscle
Superior 99.0 (2.1) 88.9 (11.2) 99.6 (0.9) 99.0 (1.6) 96.2 (3.7) 89.4 (10.7) 100.0 (0.1)
Middle 98.0 (5.3) 69.3 (31.3) 99.8 (0.5) 98.3 (5.4) 99.3 (2.5) 89.6 (14.9) 100.0 (0.0)
Inferior 98.9 (2.4) 84.5 (29.3) 99.9 (0.4) 99.4 (1.5) 99.8 (0.7) 99.3 (1.8) 100.0 (0.0)
Organs not shown scored 100(0.0) in all perturbations.
* Columns combine r = 5, 6, and 8 mm.
y Column combine 4 perturbations.
z Columns combine 3 perturbations.
x Column combine a/b = 2.4, 2.7, 3.3, and 3.6 Gy.
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soft-tissue contrast, such as magnetic resonance imaging
scans, could be used. However, it should always be consid-
ered that dose addition is an approximation of the true
dose accumulation, and that the accuracy of the method
should be taken into account when applying it in clinical
practice.
In the present study, the total dose to the tumor was not
calculated. Besides the large changes happening to the target
volume because of catheter implantation, several studies
have found that target volumes shrink during EBRT treat-
ment (21). Dose accumulation for a regressing mass requires
further research to handle disappearing tissue properly.
Table 3 compiles the differences between approximated
D1, mean dose, and D99 (by adding the separate values for
EBRT and BT) and D1, mean dose, and D99 using nonrigid
registration. Large differences were found for D1 (#25.6
Gy). The differences were smaller for mean dose and D99
(#2.6 Gy and 1.7 Gy, respectively). For large quality-of-
life studies in which mean doses are summed up, such as
the study by Teguh et al. (5), differences of this scale of mag-
nitude are probably negligible. However, this approximation
assumes modest deformations, which may not hold for other
sites. Because of the low number of patients, these results
should be interpreted with caution.
Apart from cases of head-and-neck cancer (10), our non-
rigid registration framework has been used in other studies to
analyze the deformation of the prostate and the seminalvesicles for prostate cancer patients (22) and for cervix can-
cer patients experiencing extreme deformations as a result of
bladder filling variations (23). Based on this experience and
the results described in this study, we expect our method for
dose addition to be applicable to other sites treated with
combined modality treatment (e.g., prostate and gyneco-
logic sites).
The method can also accumulate dose distributions from
other radiation modalities. Dose accumulation can also be
used to optimize radiation treatment plans that considering
dose previously delivered to the patient (e.g., optimizing
BT plans taking the EBRT dose into account). Also, using
a better total dose approximation, treatment-related toxicity
and dose–effect relationships can be determined more
accurately.CONCLUSION
We have presented a reliable and robust method that al-
lows adding 3D dose distributions of combined EBRT and
BT for organs at risk in patients with oropharyngeal cancer.
Further improvements, for example in areas with steep dose
gradient, can be expected if structures inside the organs can
be extracted in the images and used in the nonrigid registra-
tion. Optimization of BT plans while taking into account the
EBRT dose already delivered, and replanning in adaptive
strategies, are promising new possibilities.REFERENCES1. Levendag P, Nijdam W, Noever I, et al. Brachytherapy versus
surgery in carcinoma of tonsillar fossa and/or soft palate:
Late adverse sequelae and performance status: Can we be
more selective and obtain better tissue sparing? Int J Radiat
Oncol Biol Phys 2004;59:713–724.2. Pearce A, Craighead P, Kay I, et al. Brachytherapy for carci-
noma of the cervix: A Canadian survey of practice patterns in
a changing era. Radiother Oncol 2009;91:194–196.
3. Zelefsky MJ, Nedelka MA, Arican ZL, et al. Combined
brachytherapy with external beam radiotherapy for localized
3D dose addition of EBRT and BT using nonrigid registration d E. M. VASQUEZ OSORIO et al. 1277prostate cancer: Reduced morbidity with an intraoperative bra-
chytherapy planning technique and supplemental intensity-
modulated radiation therapy. Brachytherapy 2008;7:1–6.
4. Ares C, Popowski Y, Pampallona S, et al. Hypofractionated
boost with high-dose-rate brachytherapy and open magnetic
resonance imaging-guided implants for locally aggressive
prostate cancer: A sequential dose-escalation pilot study. Int
J Radiat Oncol Biol Phys 2009;75:656–663.
5. Teguh DN, Levendag PC, Noever I, et al. Treatment techniques
and site considerations regarding dysphagia-related quality of
life in cancer of the oropharynx and nasopharynx. Int J Radiat
Oncol Biol Phys 2008;72:1119–1127.
6. Steel GG, editor. Basic clinical radiobiology. London: Hodder
Arnold; 2002.
7. Chui H, Rangarajan A. A new point matching algorithm for
non-rigid registration. Computer Vision and Image Under-
standing 2003;89:114–141.
8. Vasquez Osorio EM, Hoogeman MS, Bondar L, et al. A novel
flexible framework with automatic feature correspondence
optimization for nonrigid registration in radiotherapy. Med
Phys 2009;36:2848–2859.
9. Bondar L, Hoogeman MS, Vasquez Osorio EM, et al. A
symmetric nonrigid registration method to handle large organ
deformations in cervical cancer patients. Med Phys 2010;37:
3760–3772.
10. Vasquez Osorio EM, Hoogeman MS, Al-Mamgani A, et al.
Local anatomic changes in parotid and submandibular glands
during radiotherapy for oropharynx cancer and correlation
with dose, studied in detail with nonrigid registration. Int J
Radiat Oncol Biol Phys 2008;70:875–882.
11. Kolkman-Deurloo IK. Intraoperative HDR brachytherapy:
Present and future [PhD thesis]. Rotterdam: Erasmus Univer-
sity; 2006.
12. Ibanez L, Schroeder W, Ng L, et al. The ITK software guide.
New York: Kitware Inc; 2005.13. Wendling M, Zijp LJ, McDermott LN, et al. A fast algorithm
for gamma evaluation in 3D. Med Phys 2007;34:1647–1654.
14. Bookstein F. Principal warps: Thin-plate splines and the
decomposition of deformations. IEEE Trans Pattern Anal
Mach Intell 1989;11:567–585.
15. Fowler JF. Sensitivity analysis of parameters in linear-
quadratic radiobiologic modeling. Int J Radiat Oncol Biol
Phys 2009;73:1532–1537.
16. Rosu M, Chetty IJ, Balter JM, et al. Dose reconstruction in
deforming lung anatomy: Dose grid size effects and clinical
implications. Med Phys 2005;32:2487–2495.
17. Schaly B, Kempe JA, Bauman GS, et al. Tracking the dose
distribution in radiation therapy by accounting for variable
anatomy. Phys Med Biol 2004;49:791–805.
18. Brock KK, McShan DL, Ten Haken RK, et al. Inclusion of
organ deformation in dose calculations. Med Phys 2003;30:
290–295.
19. Chi Y, Liang J, Yan D. A material sensitivity study on the
accuracy of deformable organ registration using linear biome-
chanical models. Med Phys 2006;33:421–433.
20. Zhong H, Kim J, Chetty IJ. Analysis of deformable image
registration accuracy using computational modeling. Med
Phys 2010;37:970–979.
21. Robar JL, Day A, Clancey J, et al. Spatial and dosimetric
variability of organs at risk in head-and-neck intensity-modu-
lated radiotherapy. Int J Radiat Oncol Biol Phys 2007;68:
1121–1130.
22. van der Wielen GJ, Incrocci TFML, Kirkels WJ, et al.
Deformation of the prostate and seminal vesicles relative to
intraprostatic fiducial markers. Int J Radiat Oncol Biol Phys
2008;72:1604–1611.
23. Bondar M, Hoogeman M, Dhawtal G, et al. TU-D-BRC-06:
Towards online image guided radiotherapy for cervical cancer:
Accurate cervix-uterus prediction based on measured bladder
volumes. AAPM 2009;36:2735. 2735.
